Lefamulin is a pleuromutilin antibiotic that inhibits bacterial protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of transfer RNA.
Pharmacokinetics
Indications
Lefamulin is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms:
-
Streptococcus pneumoniae
-
Staphylococcus aureus (methicillin-susceptible isolates
-
Haemophilus influenzae
-
Legionella pneumophila
-
Mycoplasma pneumoniae
-
Chlamydophila pneumoniae
Contraindications
Use in Pregnancy and Breastfeeding
Animal reproduction studies with lefamulin show some risk, and no adequate, well-controlled studies have been done in pregnant women. Alternatives to lefamulin should be considered in pregnant women until better safety data are available. Females with reproductive potential should use contraception while on therapy and for 2 days after the last dose.
Animal lactation studies suggest that lefamulin concentrates in breast milk. It is advised that lactating women taking lefamulin pump and discard while taking lefamulin and for 2 days after the last dose.
